Opdivo Price Cut “Unavoidable” to Maintain Universal Healthcare: JMA Chief

A 50% price slash for Ono Pharmaceutical’s immuno-oncology med Opdivo (nivolumab) hammered out on November 16 was “unavoidable” to keep Japan’s universal healthcare system afloat, Yoshitake Yokokura, president of the Japan Medical Association (JMA), said. “The emergency step was unavoidable...read more